Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection
Netanya G. Sandler(National Institutes of Health), Daniel C. Douek(National Institutes of Health), David E. Kleiner, T. Jake Liang(National Institutes of Health), Mary Demino(National Institutes of Health), Rebecca Siegel(National Institutes of Health), Steven G. Deeks(University of California, San Francisco), Theo Heller(National Institutes of Health), Jason Eccleston(National Institutes of Health), Annelys Roque(National Institutes of Health), Christopher Koh(National Institutes of Health)
Cited by 310
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k